Pasteur Sanofi/Centocor
This article was originally published in The Gray Sheet
Executive Summary
Ink non-exclusive worldwide distribution pact in the cancer field. Under the terms of the deal, Pasteur Sanofi Diagnostics will distribute, in conjunction with its own Access automated instrument, five tumor markers developed by Centocor: CA 19-9, CA 125, CA 15-3, CA 72-4, and PSA. The markers add to the CEA and alpha-fetoprotein tumor markers previously developed by Daiichi Pure Chemicals, Pasteur Sanofi Diagnostics' partner and exclusive distributor in Japan. Sanofi began marketing the Access in mid- 1993. The analyzer is available with 15 assays worldwide and 13 in the U.S